What is IRIDEX's stock price target for 2024?

0 analysts have issued 12-month target prices for IRIDEX's stock. Their IRIX share price targets range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 22.2%. View analysts price targets for IRIX or view top-rated stocks among Wall Street analysts .

How have IRIX shares performed in 2023?

IRIDEX's stock was trading at $2.01 at the beginning of the year. Since then, IRIX shares have increased by 27.9% and is now trading at $2.57. View the best growth stocks for 2023 here .

Are investors shorting IRIDEX?

IRIDEX saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 319,200 shares, an increase of 79.9% from the October 31st total of 177,400 shares. Based on an average trading volume of 129,600 shares, the days-to-cover ratio is presently 2.5 days. Approximately 2.6% of the company's shares are sold short. View IRIDEX's Short Interest .

When is IRIDEX's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our IRIX earnings forecast .

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) announced its earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The medical equipment provider had revenue of $13.26 million for the quarter, compared to the consensus estimate of $11.90 million. IRIDEX had a negative trailing twelve-month return on equity of 49.98% and a negative net margin of 14.21%. During the same quarter in the prior year, the company posted ($0.12) EPS.

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?

7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com . Theodore A. Boutacoff has an approval rating of 64% among the company's employees.

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA) , Trevena (TRVN) , CTI BioPharma (CTIC) , Agile Therapeutics (AGRX) , Genocea Biosciences (GNCA) , Idera Pharmaceuticals (IDRA) , Lipocine (LPCN) , Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX) .

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by many different institutional and retail investors. Top institutional investors include AMH Equity Ltd (3.93%), Perkins Capital Management Inc. (0.25%), Acadian Asset Management LLC (0.18%), Wolverine Trading LLC (0.00%), FNY Investment Advisers LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Nandini Devi and Robert Earle Grove . View institutional ownership trends .

How do I buy shares of IRIDEX?

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

IRIDEX Stock Price, News & Analysis (NASDAQ:IRIX)

$2.57

+0.19 (+7.98%)

(As of 11/28/2023 ET)

Compare

Today's Range: $2.30
▼
$2.59
50-Day Range: $1.90
▼
$3.28
52-Week Range: $1.31
▼
$3.48

Volume: 77,698 shs
Average Volume: 50,444 shs
Market Capitalization: $41.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

IRIDEX MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 22.2% Downside
$2.00 Price Target
Short Interest: Healthy
2.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.85
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.50) to ($0.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.83 out of 5 stars

Computer And Technology Sector

592nd out of 597 stocks

Electromedical Equipment Industry

22nd out of 22 stocks

0.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $2.00, IRIDEX has a forecasted downside of 22.2% from its current price of $2.57.
Amount of Analyst Coverage
IRIDEX has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.64% of the float of IRIDEX has been sold short.
Short Interest Ratio / Days to Cover
IRIDEX has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in IRIDEX has recently increased by 79.93%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
IRIDEX does not currently pay a dividend.
Dividend Growth
IRIDEX does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IRIX.

3.3

News and Social Media Coverage

News Sentiment
IRIDEX has a news sentiment score of 1.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for IRIDEX this week, compared to 0 articles on an average week.
Search Interest
Only 2 people have searched for IRIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added IRIDEX to their MarketBeat watchlist in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IRIDEX insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.20% of the stock of IRIDEX is held by insiders.
Percentage Held by Institutions
Only 23.95% of the stock of IRIDEX is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for IRIDEX are expected to grow in the coming year, from ($0.50) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IRIDEX is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IRIDEX is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IRIDEX has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IRIDEX Stock (NASDAQ:IRIX)

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IRIX Stock News Headlines

November 27, 2023 | finance.yahoo.com

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

November 17, 2023 | finanznachrichten.de

IRIDEX Corporation: Iridex Reports Third Quarter 2023 Financial Results and Business Update

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 14, 2023 | benzinga.com

Iridex: Q3 Earnings Insights

November 14, 2023 | finance.yahoo.com

Iridex Reports Third Quarter 2023 Financial Results and Business Update

November 13, 2023 | finance.yahoo.com

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

November 9, 2023 | morningstar.com

IRIDEX Corp IRIX

November 2, 2023 | msn.com

Iridex Reimbursement Chaos Presents Buying Opportunity

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 1, 2023 | msn.com

Wall Street Set to Open Mixed Ahead of Federal Reserve Meeting

November 1, 2023 | benzinga.com

Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge

November 1, 2023 | markets.businessinsider.com

Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged

November 1, 2023 | msn.com

BYU, WE and IRIX among pre-market losers

November 1, 2023 | benzinga.com

US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected

October 26, 2023 | finance.yahoo.com

Iridex to Report Third Quarter Financial Results on November 14, 2023

October 10, 2023 | finance.yahoo.com

IRIDEX's (NASDAQ:IRIX) growing losses don't faze investors as the stock surges 18% this past week

August 30, 2023 | finanznachrichten.de

IRIDEX Corporation: Iridex Announces Strategic Review to Unlock Shareholder Value

August 29, 2023 | seekingalpha.com

Iridex announces review of strategic alternatives, stock rises

August 29, 2023 | finance.yahoo.com

Iridex Announces Strategic Review to Unlock Shareholder Value

August 11, 2023 | markets.businessinsider.com

Iridex Reports Second Quarter 2023 Financial Results

August 9, 2023 | markets.businessinsider.com

IRIDEX earnings preview: what Wall Street is expecting

August 9, 2023 | finance.yahoo.com

We Think IRIDEX (NASDAQ:IRIX) Needs To Drive Business Growth Carefully

July 28, 2023 | finance.yahoo.com

Iridex to Report Second Quarter Financial Results on August 10, 2023

June 21, 2023 | finance.yahoo.com

Zacks Industry Outlook Highlights IPG Photonics and IRIDEX

June 8, 2023 | finance.yahoo.com

IRIDEX Corporation's (NASDAQ:IRIX) Price Is Right But Growth Is Lacking

May 18, 2023 | finance.yahoo.com

Iridex (IRIX) Is Attractively Priced Despite Fast-paced Momentum

May 11, 2023 | msn.com

Iridex: Q1 Earnings Insights

See More Headlines

Receive IRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/11/2021
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Computer and Technology
Current Symbol: NASDAQ:IRIX
CUSIP: N/A
CIK: 1006045
Web: www.iridex.com
Phone: (650) 940-4700
Fax: 650-940-4710
Employees: 130
Year Founded: 1989

Price Target and Rating

Average Stock Price Target: $2.00
High Stock Price Target: $2.00
Low Stock Price Target: $2.00
Potential Upside/Downside: -22.2%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,550,000.00
Net Margins: -14.21%
Pretax Margin: -14.13%
Return on Equity: -49.98%
Return on Assets: -19.36%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.64
Quick Ratio: 1.66

Sales & Book Value

Annual Sales: $56.97 million
Price / Sales: 0.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.08 per share
Price / Book: 2.38

Miscellaneous

Outstanding Shares: 16,250,000
Free Float: 15,241,000
Market Cap: $41.76 million
Optionable: Not Optionable
Beta: 0.88

Social Links

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. David I. Bruce (Age 64)
President, CEO & Director
Comp: $459.31k
Mr. Patrick Mercer (Age 51)
Chief Operating Officer
Comp: $385.51k
Ms. Leigh Salvo
Head of Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IRIX Stock Analysis - Frequently Asked Questions

What is IRIDEX's stock price target for 2024?: 0 analysts have issued 12-month target prices for IRIDEX's stock. Their IRIX share price targets range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 22.2%.
View analysts price targets for IRIX or view top-rated stocks among Wall Street analysts.
How have IRIX shares performed in 2023?: IRIDEX's stock was trading at $2.01 at the beginning of the year. Since then, IRIX shares have increased by 27.9% and is now trading at $2.57.
View the best growth stocks for 2023 here.
Are investors shorting IRIDEX?: IRIDEX saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 319,200 shares, an increase of 79.9% from the October 31st total of 177,400 shares. Based on an average trading volume of 129,600 shares, the days-to-cover ratio is presently 2.5 days. Approximately 2.6% of the company's shares are sold short.
View IRIDEX's Short Interest.
When is IRIDEX's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our IRIX earnings forecast.
How were IRIDEX's earnings last quarter?: IRIDEX Co. (NASDAQ:IRIX) announced its earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The medical equipment provider had revenue of $13.26 million for the quarter, compared to the consensus estimate of $11.90 million. IRIDEX had a negative trailing twelve-month return on equity of 49.98% and a negative net margin of 14.21%. During the same quarter in the prior year, the company posted ($0.12) EPS.

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?: 7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees.
What other stocks do shareholders of IRIDEX own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX).
Who are IRIDEX's major shareholders?: IRIDEX's stock is owned by many different institutional and retail investors. Top institutional investors include AMH Equity Ltd (3.93%), Perkins Capital Management Inc. (0.25%), Acadian Asset Management LLC (0.18%), Wolverine Trading LLC (0.00%), FNY Investment Advisers LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Nandini Devi and Robert Earle Grove.
View institutional ownership trends.
How do I buy shares of IRIDEX?: Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IRIX) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial